By Brigette Currin 2 minute read

Glyconics© is delighted to announce the appointment of Dr Joanne Phoenix as a non-executive board director with immediate effect.

Dr Phoenix – who has 20 years’ experience of working with life science and IP-based businesses – has successfully grown business operations in both the private and public sector. Poignantly, she was responsible for delivering the first commercially available automated diagnostic test for diabetic retinopathy screening into the National Health Service (NHS).

Her appointment – replacing Dr Savvas Neophytou as board representative from Glyconics’ lead investor, Deepbridge Capital – comes at a particularly exciting stage in Glyconics growth, development and recognition.

The innovative diagnostics company – which uses Infrared Spectroscopy to analyse samples for specific biomarkers characteristic of diseases such as diabetes and chronic obstructive pulmonary disease (COPD) – was recently listed by as one of the 80 standout European start-up pioneers driving seismic change in the post-pandemic world, “cracking healthcare with technology”.

Glyconics© was also awarded a coveted Seal of Excellence certificate for its project developing a compact cost-effective way of using IR Spectroscopy for point-of-care testing. Until now, IR Spectroscopy could only be undertaken in a laboratory by highly trained staff.

Dr Phoenix says: “I am honoured to be working with the team at Glyconics© who consistently show such drive and commitment to the product range they have in development. The company has an exciting approach to the early identification of diabetes and exacerbating COPD, which is particularly timely now when there is a need to keep such patients out of hospital.

“Additional diagnostic approaches in the pipeline also add to the attractiveness and potential of Glyconics©, and I look forward to working with the entire team and bringing the potential through to fruition.”


Dr Berwyn Clarke, Executive Chairman at Glyconics, says: “Not only does Joanne bring a range of experience across life science and IP-based businesses, she also has broad-based experience working with early-stage, venture capital-backed companies. I am delighted to be welcoming her to the board, and we look forward to working with her at this exciting time for the business.

“We would also like to take this opportunity to thank Savvas for his much-valued contribution to the company.”